A Study to Assess how Well and Safely Elafibranor Works in Adult Participants with Primary Sclerosing Cholangitis

Recruiting
99 years or below
All
Phase N/A
5 participants needed
1 Location

Brief description of study

This phase III, multicenter, randomized, double-blind, placebo-controlled study aims to further evaluate the efficacy and safety of elafibranor 120 mg/day in adult participants with primary sclerosing cholangitis (PSC). The primary objective is to evaluate the efficacy of daily oral administration of elafibranor 120 mg compared to placebo based on time to first occurrence of clinical outcome events in adult participants with PSC. The study consists of three periods: an up-to 10-week screening period; an event-driven treatment period; and a 4-week safety follow-up after the last dose of study intervention.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 01 Sep 2026. Study ID: 26-7705

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Please provide your preferred way of contact
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center